NISHIYAMA NAOTAKA 西山直隆

… Alternative Names

NISHIYAMA Naotaka 西山直隆

Less

Researcher Number	70619030
Other IDs
Affiliation (Current)	2025: 富山大学, 学術研究部医学系, 准教授
Affiliation (based on the past Project Information) *help	2023: 富山大学, 学術研究部医学系, 准教授 2019 – 2022: 富山大学, 学術研究部医学系, 講師 2018: 富山大学, 大学院医学薬学研究部(医学), 講師 2012 – 2017: 札幌医科大学, 医学部, 助教
Review Section/Research Field	Principal Investigator Basic Section 56030:Urology-related / Urology Except Principal Investigator Basic Section 56030:Urology-related / Urology
Keywords	Principal Investigator 尿路上皮癌 / 新規治療開発 / 化学療法抵抗性 / ADAMTS1 / 膀胱がん / エピゲノム解析 / 切除不能尿路上皮がん / ヒストン修飾 / エピジェネティクス治療 / 転移性膀胱癌 … More / 化学療法耐性 / 2次治療 / 5-Aza-CdR / エピジェネティクス / 膀胱癌 / 薬剤抵抗性膀胱癌 / GMFG / AKAP12 / HIST1H1C / FN1 / ゲノム網羅的解析 … More Except Principal Investigator 腎細胞癌 / CpGアイランドメチル化形質 / オーロラキナーゼ / メチル化 / CpGアイランド / 個別化治療 / コンパニオン診断 / 腎細胞がん / ヒストン修飾 / DNAメチル化 / DNAメチル基転移酵素阻害剤 / 尿路上皮癌 / 膀胱癌 / 薬剤耐性化 / ヒストン脱アセチル化酵素阻害剤 / 5-Aza-CdR / ゲノム網羅的染色体構造解析 / ゲムシタビン耐性株 / シスプラチン耐性株 / エピジェネティクス治療 / 転移性膀胱癌 / 予後予測マーカー / エピジェネティック治療 / 化学療法抵抗性 / 転移性尿路上皮癌 Less

CIMP陽性腎細胞がんに対するオーロラキナーゼ阻害薬治療確立のための前臨床研究
- Principal Investigator
  
  北村寛
- Project Period (FY)
  2023 – 2025
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  University of Toyama
尿路上皮がんに対する新規エピゲノム解析による治療効果予測バイオマーカー開発Principal Investigator
- Principal Investigator
  
  西山直隆
- Project Period (FY)
  2023 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  University of Toyama
Established epigenetic treatment for chemotherapy-resistant metastatic bladder cancerPrincipal Investigator
- Principal Investigator
  
  Nishiyama Naotaka
- Project Period (FY)
  2019 – 2021
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  University of Toyama
Development of personalized therapy for patients with CpG island methylator phenotype renal cell carcinoma
- Principal Investigator
  
  Hiroshi Kitamura
- Project Period (FY)
  2019 – 2022
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 56030:Urology-related
- Research Institution
  University of Toyama
A potential role of aberrant DNA methylation in the chemoresistance in bladder cancer cells
- Principal Investigator
  
  Masumori Naoya
- Project Period (FY)
  2016 – 2018
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Sapporo Medical University
尿路上皮がんにおけるＡＤＡＭＴＳ１遺伝子の解析および転移予測指標・治療標的の確立Principal Investigator
- Principal Investigator
  
  西山直隆
- Project Period (FY)
  2014 – 2015
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Urology
- Research Institution
  Sapporo Medical University
Analysis of the tumor related genes may serves as targets for therapy and construction of predictive models in patients with bladder cancer.Principal Investigator
- Principal Investigator
  
  NISHIYAMA Naotaka
- Project Period (FY)
  2012 – 2013
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Urology
- Research Institution
  Sapporo Medical University

All 2024 2020 2019 2018 2017 2015 2014 2013 2012 Other

All Journal Article Presentation

[Journal Article] Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer2018
- Author(s)
  Shindo Tetsuya、Niinuma Takeshi、Nishiyama Naotaka、Shinkai Nobuo、Kitajima Hiroshi、Kai Masahiro、Maruyama Reo、Tokino Takashi、Masumori Naoya、Suzuki Hiromu
- Journal Title
  
  Oncotarget
  
  Volume: 9 Issue: 36 Pages: 24457-24469
- DOI
  10.18632/oncotarget.25326
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-16K07122, KAKENHI-PROJECT-18K15220, KAKENHI-PROJECT-16K11017, KAKENHI-PROJECT-16H06279
[Journal Article] Construction of predictive models for cancer-specific survival of patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin: Results from a multicenter retrospective study.2014
- Author(s)
  Naotaka Nishiyama, Hiroshi Kitamura, Hiroshi Hotta, Atsushi Takahashi, Masahiro Yanase, Naoki Itoh, Hitoshi Tachiki, Noriomi Miyao, Masanori Matsukawa, Yasuharu Kunishima, Keisuke Taguchi, Naoya Masumori
- Journal Title
  
  Jpn J Clin Oncol
  
  Volume: ４４ Issue: 11 Pages: 1101-1108
- DOI
  10.1093/jjco/hyu119
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26462417
[Journal Article] Clinicopapathological analysis of patients with non-muscle-invasive bladder cancer: Prognostic value and clinical reliability of the 2004 WHO classification system2013
- Author(s)
  Nishiyama N, Kitamura H, Maeda T, Takahashi S, Masumori N, et al.
- Journal Title
  
  Japanse Journal of Clinical Oncology
  
  Volume: 43 Pages: 1124-1131
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24791656
[Journal Article] Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system2013
- Author(s)
  Nishiyama N, Kitamura H, Maeda T, Takahashi S, Masumori N, Hasegawa T, Tsukamoto T
- Journal Title
  
  Jpn J Clin Oncol
  
  Volume: 43 Issue: 11 Pages: 1124-1131
- DOI
  10.1093/jjco/hyt120
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592342, KAKENHI-PROJECT-24791656
[Journal Article] Clinicopathological analysis of patients with nonmuscle- invasive bladder cancer who under- went radical cystectomy2012
- Author(s)
  Nishiyama N, Kitamura H, Mutoh M, Yanase M, Iwaki H, Hasegawa T, Tsukamoto T
- Journal Title
  
  Surg Sci
  
  Volume: 3 Issue: 07 Pages: 347-352
- DOI
  10.4236/ss.2012.37068
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-23592342, KAKENHI-PROJECT-24791656
[Presentation] Can expression for AURKA serve as a prognostic factor in advanced RCC treated with immune checkpoint inhibitors (ICIs) in first-line therapy2024
- Author(s)
  Fujiki R, Nishiyama N, Mizutani Y, Shizu M, Kuribayashi Y, Ikehata Y, Kitamura H
- Organizer
  第111回日本泌尿器科学会総会
- Data Source
  KAKENHI-PROJECT-23K08712
[Presentation] 抗癌剤耐性膀胱癌細胞株におけるDNAメチル化の変化およびin vitroおよびin vivoでのDNA脱メチル化剤の抗癌剤感受性への効果2020
- Author(s)
  西山　直隆
- Organizer
  第29回　泌尿器科分子・細胞研究会
- Data Source
  KAKENHI-PROJECT-19K09706
[Presentation] 抗癌剤耐性膀胱癌細胞株におけるDNAメチル化の変化およびDNA脱メチル化剤の抗癌剤感受性への効果2019
- Author(s)
  西山　直隆
- Organizer
  第107回日本泌尿器科学会総会
- Data Source
  KAKENHI-PROJECT-19K09706
[Presentation] DNA methylation inhibitors could re-sensitize drug-resistance bladder cancer cells in vitro and in vivo.2018
- Author(s)
  Nishiyama N, Yi S, Daneshmand S, Jones PA, Djaladat H, Masumori N, Liang G
- Organizer
  AUA 2018 Annual Meeting, San Francisco, USA, 2016
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K11017
[Presentation] 抗癌剤耐性膀胱癌細胞に株におけるDNAメチル化の変化およびDNA脱メチル化の抗癌剤感受性への効果2017
- Author(s)
  西山直隆、新海信雄、進藤哲哉、鈴木拓、舛森直哉
- Organizer
  第11回日本エピジェネティクス研究会年会　東京　2017
- Data Source
  KAKENHI-PROJECT-16K11017
[Presentation] DNA methylation inhibitors could re-sensitize drug-resistance bladder cancer cells2017
- Author(s)
  新海信雄、西山直隆、進藤哲哉、鈴木拓、舛森直哉
- Organizer
  AUA 2017 Annual Meeting, Boston, USA, 2017
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-16K11017
[Presentation] 尿路上皮がんにおけるGC療法耐性化とADAMTS1遺伝子発現との関係：予後予測指標としての可能性2015
- Author(s)
  西山　直隆
- Organizer
  第103回日本泌尿器科学会総会
- Place of Presentation
  石川県立音楽堂，他（石川県金沢市）
- Year and Date
  2015-04-18
- Data Source
  KAKENHI-PROJECT-26462417
[Presentation] Clinicopathological analysis of patients with nonmuscle-invasive bladder cancer: Prognostic value and clinical reliability of the WHO grading system of 20042013
- Author(s)
  Nishiyama N, Kitamura H, Masumori N, et al.
- Organizer
  American Urological Association 2013 Annual Meeting
- Place of Presentation
  San Diego in USA
- Data Source
  KAKENHI-PROJECT-24791656
[Presentation] Clinico- pathological analysis of patients with nonmuscle-invasive bladder cancer : Prognostic value and clinical reliability of the WHO grading system of 20042013
- Author(s)
  Nnishiyama N, Kitamura H, Masumori N, Hasegawa T, Tsukamoto T
- Organizer
  AUA 2013 Annual Meeting
- Place of Presentation
  San Diego, USA
- Data Source
  KAKENHI-PROJECT-24791656
[Presentation] BCG failure をきたした筋層非浸潤性膀胱癌の予後に関する後ろ向き・多施設共同研究2013
- Author(s)
  西山直隆, 進藤哲哉, 堀田裕, 高橋敦, 柳瀬雅裕, 伊藤直樹, 立木仁, 宮尾則臣, 松川雅則, 国島康晴, 田口圭介, 北村寛, 舛森直哉
- Organizer
  第51回日本癌治療学会総会
- Place of Presentation
  京都
- Data Source
  KAKENHI-PROJECT-24791656
[Presentation] Overexpression of ADAMTS1 is associated with gemcitabine/cisplatin resistance and poor prognosis in urothelial carcinoma of the bladder
- Author(s)
  Naotaka Nishiyama, Hiroshi Kitamura, Ryuta Inoue, Sachiyo Nishida, Megumi Hirobe, Satoshi Takahashi, Naoya Masumori
- Organizer
  第73回日本癌学会学術総会
- Place of Presentation
  横浜
- Year and Date
  2014-09-25 – 2014-09-27
- Data Source
  KAKENHI-PROJECT-26462417

1. Hiroshi Kitamura (00404674)

# of Collaborated Projects: 5 results

# of Collaborated Products: 5 results
2. 新井恵吏 (40446547)

# of Collaborated Projects: 3 results

# of Collaborated Products: 0 results
3. Masumori Naoya (20295356)

# of Collaborated Projects: 2 results

# of Collaborated Products: 6 results
4. 金井弥栄 (00260315)

# of Collaborated Projects: 2 results

# of Collaborated Products: 0 results
5. 進藤哲哉 (80749292)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
6. 新海信雄 (40772398)

# of Collaborated Projects: 1 results

# of Collaborated Products: 2 results
7. 鈴木拓 (20381254)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
8. 小林恭 (00642406)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
9. 塚本泰司

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
10. 時野隆至

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

NISHIYAMA NAOTAKA 西山 直隆

NISHIYAMA Naotaka 西山 直隆

Research Projects

Research Products

Co-Researchers

CIMP陽性腎細胞がんに対するオーロラキナーゼ阻害薬治療確立のための前臨床研究

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

尿路上皮がんに対する新規エピゲノム解析による治療効果予測バイオマーカー開発Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Established epigenetic treatment for chemotherapy-resistant metastatic bladder cancerPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Development of personalized therapy for patients with CpG island methylator phenotype renal cell carcinoma

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

A potential role of aberrant DNA methylation in the chemoresistance in bladder cancer cells

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

尿路上皮がんにおけるＡＤＡＭＴＳ１遺伝子の解析および転移予測指標・治療標的の確立Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

Analysis of the tumor related genes may serves as targets for therapy and construction of predictive models in patients with bladder cancer.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer2018

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Construction of predictive models for cancer-specific survival of patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin: Results from a multicenter retrospective study.2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Clinicopapathological analysis of patients with non-muscle-invasive bladder cancer: Prognostic value and clinical reliability of the 2004 WHO classification system2013

Author(s)

Journal Title

Data Source

[Journal Article] Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system2013

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Clinicopathological analysis of patients with nonmuscle- invasive bladder cancer who under- went radical cystectomy2012

Author(s)

Journal Title

DOI

Data Source

[Presentation] Can expression for AURKA serve as a prognostic factor in advanced RCC treated with immune checkpoint inhibitors (ICIs) in first-line therapy2024

Author(s)

Organizer

Data Source

[Presentation] 抗癌剤耐性膀胱癌細胞株におけるDNAメチル化の 変化およびin vitroおよびin vivoでのDNA脱メチル化剤の抗癌剤感受性への効果2020

Author(s)

Organizer

Data Source

[Presentation] 抗癌剤耐性膀胱癌細胞株におけるDNAメチル化の変化およびDNA脱メチル化剤の抗癌剤感受性への効果2019

NISHIYAMA NAOTAKA 西山直隆

NISHIYAMA Naotaka 西山直隆

[Presentation] 抗癌剤耐性膀胱癌細胞株におけるDNAメチル化の変化およびin vitroおよびin vivoでのDNA脱メチル化剤の抗癌剤感受性への効果2020